Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
233 studies found for:    ACRODYSOSTOSIS 2, WITH OR WITHOUT HORMONE RESISTANCE
Show Display Options
Rank Status Study
1 Active, not recruiting Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
Conditions: Breast Cancer;   Breast Neoplasm
Intervention: Drug: Pazopanib
2 Recruiting Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Condition: Neoplasms
Interventions: Drug: Fulvestrant;   Drug: Vandetanib
3 Completed Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Conditions: Hormone Resistant Prostate Cancer;   Metastatic Prostate Cancer
Interventions: Drug: docetaxel;   Drug: estramustine;   Drug: prednisone
4 Completed
Has Results
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
Conditions: HIV-Associated Lipodystrophy Syndrome;   Insulin Resistance;   HIV Infections;   Metabolic Syndrome X;   Body Weight Changes
Interventions: Drug: Rosiglitazone;   Drug: Recombinant human growth hormone + rosiglitazone
5 Recruiting Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide
Conditions: Hormone-Resistant Prostate Cancer;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
6 Recruiting Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
Conditions: Acromegaly;   Excessive Growth Hormone Secretion;   Insulin Resistance
Intervention: Procedure: Transsphenoidal adenomectomy
7 Completed Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
Conditions: Diabetes;   Metabolic Syndrome;   Insulin Resistance
Intervention: Drug: pegvisomant
8 Terminated Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: orteronel;   Other: laboratory biomarker analysis
9 Active, not recruiting Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone
10 Not yet recruiting Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cabazitaxel;   Drug: Prednisone
11 Active, not recruiting Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: cabozantinib-s-malate;   Radiation: fluorine F 18 d-FMAU;   Procedure: positron emission tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Suspended Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Prostate Cancer;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis;   Other: questionnaire administration;   Drug: doxorubicin-GnRH agonist conjugate AEZS-108
13 Not yet recruiting Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Trametinib
14 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine
15 Active, not recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Recruiting Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Cabazitaxel;   Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone
17 Not yet recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
18 Active, not recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
19 Completed
Has Results
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Sipuleucel-T;   Drug: Tasquinimod
20 Recruiting Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years